Chemomab Therapeutics Ltd (CMMB) is not a strong buy at the moment for a beginner, long-term investor. The lack of positive financial performance, absence of trading signals, and no significant catalysts make it a hold rather than a buy. The investor should wait for clearer signs of growth or positive momentum before committing funds.

Technical Analysis

The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 51.702, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 1.505, with resistance at 1.616 and support at 1.395, suggesting limited upside potential in the short term.

Positive Catalysts

NULL identified. There is no recent news, no significant insider or hedge fund activity, and no congress trading data to suggest a positive catalyst.

Neutral/Negative Catalysts

Additionally, there is no news or trading trend to indicate a turnaround.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a significant drop in net income (-49.99% YoY), and EPS at 0 (-100% YoY). Gross margin remains at 0, showing no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

2 Analyst Rating

Wall Street analysts forecast CMMB stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.860

Low

Averages

17.5

High

Current: 1.860

Low

Averages

17.5

High

Oppenheimer

Outperform

maintain

$10 -> $25

AI Analysis

2025-08-27

Reason

Oppenheimer

Price Target

$10 -> $25

AI Analysis

2025-08-27

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Chemomab Therapeutics to $25 from $10 and keeps an Outperform rating on the shares to reflect Q2 results and management's intent to advance nebokitug in primary sclerosing cholangitis solely based on a third-party partnership, licensing or other similar transaction. The firm, which notes that its raised target reflects the potential value it sees to shareholders under an M&A or licensing scenario, points out that it also accounts for the company's 4-to-1 reverse share split.

Oppenheimer

Jeff Jones

Outperform

downgrade

$11 -> $10

2025-05-16

Reason

Oppenheimer

Jeff Jones

Price Target

$11 -> $10

2025-05-16

downgrade

Outperform

Reason

Oppenheimer analyst Jeff Jones lowered the firm's price target on Chemomab Therapeutics to $10 from $11 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 financial results, highlighting recent updates, including regulatory feedback providing clear guidance on approvable endpoints for nebokitug in PSC, and recent positive 48 weeks SPRING OLE results.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CMMB

Unlock Now

CMMB Should I Buy

CMMB Should I Buy

Should You Buy Chemomab Therapeutics Ltd (CMMB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch